Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 52.43% | -136.29% | -19.79% | -68.02% | 24.03% |
| Total Depreciation and Amortization | 0.00% | -77.27% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -76.35% | 10,764.71% | 0.85% | 1.72% | 0.87% |
| Change in Net Operating Assets | -235.49% | -55.97% | 519.06% | 112.68% | -726.33% |
| Cash from Operations | -19.89% | -61.42% | 25.91% | 26.99% | -86.12% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -17.27% | -17.29% | -0.75% | -30.79% | 287.20% |
| Total Debt Repaid | -32.95% | 18.52% | 6.67% | 56.66% | -286.16% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 133.33% | -- | -- | -- | -- |
| Cash from Financing | 36.11% | 33.76% | 0.07% | -24.59% | 287.45% |
| Foreign Exchange rate Adjustments | 111.11% | -280.00% | 150.00% | 133.33% | 97.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.69% | -600.00% | 114.35% | 34.28% | 31.14% |